NCT03799926 - Exploratory Study of ZG-801 for the Treatment of Hyperkalemia | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

November 6, 2019

Study Completion Date

February 2, 2021

Conditions

Hyperkalemia

Interventions

DRUG

patiromer

Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

DRUG

patiromer

Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

DRUG

placebo

Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

DRUG

placebo

Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)

DRUG

patiromer

Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)

DRUG

patiromer

Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)

DRUG

patiromer

Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)

DRUG

patiromer

Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)

Trial Locations (1)

Unknown

Zeria Investigative Sites, Kanagawa